Castle Biosciences announced a study validating the enhanced DecisionDx-SCC test, which integrates genetic and clinical risk factors to better predict metastasis and local recurrence in high-risk cutaneous squamous cell carcinoma (SCC) patients. The test's Class 1A result shows a 97.3% negative predictive value, supporting less intensive care for low-risk patients, while Class 2B identifies those who benefit most from adjuvant radiation therapy, reducing metastatic progression by about 50%. This refined test outperforms traditional risk assessments, aiding personalized treatment decisions and improving patient management.
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
Macy's will report its Q2 fiscal 2026 earnings on September 10, with analysts expecting adjusted EPS of $0.37 and net sales of $4.81 billion, both above company guidance. The retailer's turnaround strategy focuses on strengthening its core stores, gr...
Wells Fargo lowered its price target for Casey's General Stores to $750 from $960 after the company reported a 3.2% same-store sales growth in Q1, missing analyst expectations. Despite the sales miss, Casey's posted revenue of $5.68 billion and EPS o...
America's Car-Mart reported a 57.3% revenue decline to $145.8 million and a net loss of $69 million in Q1 fiscal 2027, driven by capital constraints that limited vehicle purchases and customer financing. Retail unit sales fell 81.9%, and vehicle inve...
